Hepatobiliary surgery in the era of immunotherapy: integrating surgical timing, immune surveillance, and recurrence prevention - Scorecard - MDSpire

Hepatobiliary surgery in the era of immunotherapy: integrating surgical timing, immune surveillance, and recurrence prevention

  • By

  • Jingyi Xu

  • Lei Yang

  • Shuang Wang

  • Liusheng Wu

  • Yuehua Liang

  • Xialin Xie

  • Wenqiang Wang

  • Lu Gao

  • Jun Yan

  • July 1, 2026

  • 0 min

Share

Clinical Scorecard: Advancements in Hepatobiliary Surgery Amidst Immunotherapy: Balancing Surgical Timing, Immune Monitoring, and Recurrence Mitigation

At a Glance

CategoryDetail
ConditionHepatobiliary malignancies including HCC and BTC
Key MechanismsInfluence of immunotherapy on surgical timing and decision-making
Target PopulationPatients with hepatobiliary cancers undergoing surgery
Care SettingSurgical oncology and multidisciplinary cancer care

Key Highlights

  • Immuno-surgical resectability integrates immune response with surgical feasibility.
  • Neoadjuvant immunotherapy shows potential for improved relapse-free survival in HCC.
  • Surgical timing must consider immune-related adverse events and tumor biology.
  • Lymphadenectomy is crucial for staging and may impact immunotherapy efficacy.
  • Pre-transplant ICI exposure requires careful management of washout periods.

Guideline-Based Recommendations

Diagnosis

  • Assess tumor extent, liver reserve, and immune-related toxicity before surgery.

Management

  • Consider neoadjuvant immunotherapy for selected patients with HCC and BTC.

Monitoring & Follow-up

  • Monitor alpha-fetoprotein or CA19-9 kinetics and liver function post-therapy.

Risks

  • Short washout periods after ICI therapy may increase rejection risk in transplant candidates.

Patient & Prescribing Data

Patients with hepatobiliary malignancies requiring surgical intervention.

ICIs and TKIs may improve surgical outcomes but require careful timing and monitoring.

Clinical Best Practices

  • Integrate imaging and biomarkers in surgical decision-making.
  • Ensure multidisciplinary evaluation for transplant candidates post-ICI therapy.
  • Reassess surgical feasibility based on tumor response and liver function.

Related Resources & Content

Original Source(s)

Related Content